Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

Part of paid clinical trials in Portland, Oregon.

Sponsor
Oregon Health and Science University
Study ID
NCT00525902
Phase
PHASE2
Status
Completed

Conditions

  • Uveitis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — DRUG
    40 mg delivered every 2 weeks by subcutaneous injection

Study Details

The purpose of this study is to assess the safety and efficacy of Adalimumab in uveitis.

Key Dates

Start date
Jan 31, 2008
Status verified
Apr 2012
Primary completion
Sep 30, 2010
Completion
Sep 30, 2010

Study Design

Enrollment
31 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Adalimumab

Primary Outcome Measure

Cumulative Endpoint [ Time Frame: 10 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Oregon Health & Science UniversityPortlandOregon97239-

Find similar trials in Portland, OR

By research site
Oregon Health & Science University· Portland, OR

Related Studies